目的 探讨胆木浸膏片联合头孢克肟治疗上呼吸道感染的临床疗效。方法 选取2017年5月-2018年5月在成都市青白江区人民医院治疗的上呼吸道感染患者92例，根据用药的不同分为对照组（46例）和治疗组（46例）。对照组口服头孢克肟分散片，100 mg/次，2次/d；治疗组在对照组基础上口服胆木浸膏片，1.5 g/次，3次/d。两组患者均治疗7 d。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状消失时间及降钙素原（PCT）、超敏C反应蛋白（hs-CRP）、白细胞介素-1β（IL-1β）、IL-10和γ-干扰素（IFN-γ）水平。结果 治疗后，对照组临床总有效率为80.43%，显著低于治疗组的97.83%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者发热、咳嗽、咽痛、咽部充血等临床症状消失时间均明显短于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清PCT、hs-CRP、IL-1β水平均显著降低（P<0.05），IL-10和IFN-γ水平显著升高（P<0.05），且治疗组患者炎症因子水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 胆木浸膏片联合头孢克肟分散片治疗上呼吸道感染能够明显改善患者临床症状，降低机体炎症反应，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Danmu Jingao Tablets combined with cefixime in treatment of upper respiratory tract infection. Methods Patients (92 cases) with upper respiratory tract infection in Chengdu Qingbaijiang People's Hospital from May 2017 to May 2018 were divided into control (46 cases) and treatment (46 cases) groups based on different treatments. Patients in the control group were po administered with Cefixime Dispersible Tablets, 100 mg/time, twice daily. Patients in the treatment group were po administered with Danmu Jingao Tablets on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, and PCT, hs-CRP, IL-1β, IL-10 IFN-γ levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.43%, which was significantly lower than 97.83% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of fever, cough sore throat and hyperemia of pharynx in the treatment group was significantly earlier than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the serum PCT, hs-CRP, and IL-1β levels in two groups were significantly decreased (P < 0.05), but IL-10 and IFN-γ levels were significantly increased (P < 0.05), and these inflammatory factors levels in the treatment group were significantly better than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Danmu Jingao Tablets combined with cefixime in treatment of upper respiratory tract infection can significantly improve the clinical symptoms, reduce the inflammatory response, which has a certain clinical application value.